<DOC>
	<DOCNO>NCT02819596</DOCNO>
	<brief_summary>This study carry see drug MEDI4736 , Savolitinib Tremelimumab use alone combination reduce size tumour patient kidney cancer . The drug test study anti-tumour effect test pre-clinical human study . MEDI4736 tremelimumab work immune system help body fight tumour cell immune cell . Savolitinib work correct faulty signal cause tumour growth . If patient eligible study decides take part , enrol one 3 stage study . - First stage : aim find optimal dose MEDI4736+savolitinib . - Second stage : patient papillary cell cancer treat MEDI4736+savolitinib . Patients clear cell cancer randomise one four treatment arm receive MEDI4736 , savolitinib , MEDI4736+savolitinib , MEDI4736+tremelimumab . - Third stage : patient test biomarkers enrolment , depend result allocate one 3 treatment ( MEDI4736 , savolitinib , MEDI4736+tremelimumab ) see certain biomarkers link drug efficacy .</brief_summary>
	<brief_title>MEDI4736 Combinations Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description>This study carry see drug MEDI4736 , Savolitinib Tremelimumab use alone combination reduce size tumour patient kidney cancer . The drug test study anti-tumour effect test pre-clinical human study . MEDI4736 tremelimumab work immune system help body fight tumour cell immune cell . Savolitinib work correct faulty signal cause tumour growth .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Adenomyoepithelioma</mesh_term>
	<mesh_term>Adenocarcinoma , Clear Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>1 . Written inform consent prior perform protocolrelated procedure , include study specific screening procedure . 2 . Age ≥ 18 year time study entry . 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 4 . Life expectancy ≥12 week 5 . Histologically confirm advanced ( amenable curative surgery radiation therapy ) metastatic ( stage IV ) renal cell cancer component either clear cell cancer papillary cancer . Patients component must enrol cohort predominant tumour type . 1 . Clear cell renal cancer patient must experience progressive disease exposure Vascular Endothelial growth rate ( VEGF ) target therapy . 2 . Papillary cell renal cancer patient must consider VEGF treatment naive treatment refractory eligible . 6 . Evidence measurable disease ( i.e. , ≥1 malignant tumour mass accurately measure least 1 dimension ≥ 20 mm conventional computerized tomography CT Scan Magnetic Resonance Imaging ( MRI ) , ≥10 mm spiral CT scan use 5 mm small contiguous reconstruction algorithm ) . Bone lesion , ascites , peritoneal carcinomatosis miliary lesion , pleural pericardial effusion , lymphangitis skin lung , cystic lesion , irradiate lesion consider measurable . 7 . Adequate normal organ , marrow coagulation function define follow criterion : 1 . Haemoglobin ≥ 9.0g/dL 2 . Absolute neutrophil count ( ANC ) ≥1.5 x 109/L ( ≥1500/L ) without growth factor support 3 . Platelet count ≥ 100 x 109 /L ( ≥100,000/L ) 4 . Total serum bilirubin ≤1.5 x institutional upper limit normal ( ULN ) ( apply subject confirm Gilbert 's syndrome [ persistent recurrent hyperbilirubinaemia predominantly unconjugated absence haemolysis hepatic pathology ] , allow consultation physician . 5 . Serum transaminase ( AST/ALT ) ≤2.5 x institutional ULN . 6 . Glomerular filtration rate ( GFR ) FR ≥40mL/min assess use standard methodology investigate site ( e.g . CockroftGault ) . 7. International Normalisation Ration ( INR ) &lt; 1.5 x institutional ULN activate partial thromboplastin time ( aPTT ) &lt; 1.5 x institutional ULN . This apply patient receive therapeutic anticoagulation . 8 . Representative formalinfixed paraffinembedded ( FFPE ) tumour block associate anonymised pathology report must available central test determine evaluable tumour assessment PDL1 Met . PDL1 Met relate test require prior study entry biomarker enrichment phase trial . ( every effort make obtain FFPE block however unstained fresh tissue slide core needle biopsy suffice ) 9 . Patients know tumour thrombus deep vein thrombosis ( DVT ) eligible stable low molecular weight heparin ( LMWH ) ≥ 4 week . 10 . Negative serum urine pregnancy test within 2 week prior first dose IMP ( female patient childbearing potential ) . Nonchildbearing potential define : 1 . Postmenopausal define age 50 year age amenorrhoeic least 12 month follow cessation exogenous hormonal treatment OR 2 . Documented irreversible surgical sterilisation hysterectomy , bilateral oophorectomy bilateral salpingectomy tubal ligation OR 3 . &lt; 50 year age amenorrhoeic 12 month follow cessation exogenous hormonal treatment Luteinizing hormone ( LH ) Follicle Stimulating Hormone ( FSH ) level within local institution postmenopausal range 11 . Agreement use adequate contraceptive measure ( Section 6.18 ) . 12 . Ability swallow retain oral medication . 13 . Willing able comply protocol duration study include undergoing treatment , schedule visit examination include follow . 1 . Participation another clinical study investigational product within 28 day prior enrolment study . 2 . Any previous treatment anti−programmed death−1 ( PD1 ) , anti−PDL1 therapeutic antibody ( include MEDI4736 ) , CD137 agonists , cMET inhibitor pathwaytargeting agent , CTLA4 . Patients limited cMET inhibitor exposure must discuss study medical monitor . 3 . Receipt last dose anticancer therapy ( chemotherapy , immunotherapy , endocrine therapy , target therapy , biologic therapy , tumour embolization , monoclonal antibody ) within 2 week five halflives anticancer therapy prior first dose study drug , radical radiotherapy within 4 week prior first dose study drug . 4 . Patients receive strong inducer CYP3A4 , strong inhibitor CYP3A4 CYP1A2 CYP3A4 substrates narrow therapeutic range within 2 week first dose study treatment ( 3 week St John 's Wort ) exclude enrolment study ( see Appendix I ) . 5 . Currently receive treatment therapeutic dos warfarin sodium . LMWH allow . 6 . Current prior use immunosuppressive medication within 21 day first dose MEDI4736 tremelimumab , exception intranasal inhaled corticosteroid systemic corticosteroid physiological dos , exceed 10 mg/day prednisone , equivalent corticosteroid . 7 . Treatment systemic immunostimulatory agent ( include limit interferon interleukin [ IL ] −2 ) within 4 week five halflives drug , whichever short , prior enrolment . 8 . Receipt live attenuate vaccination within 30 day prior study entry within 30 day receive MEDI4736 tremelimumab anticipation live , attenuated vaccine require study . 9 . Symptomatic uncontrolled brain metastasis require concurrent treatment , inclusive limited surgery , radiation and/or corticosteroid . 10 . History another primary malignancy renal cell carcinoma within 3 year prior Cycle 1 , Day 1 exception : 1 . Malignancy treat curative intent know active disease ≥ 3 year first dose study drug low potential risk recurrence . 2 . Adequately treated nonmelanoma skin cancer lentigo maligna without evidence disease . 3 . Adequately treated carcinoma situ without evidence disease e.g . cervical cancer situ localize prostate cancer treat curative intent absence prostatespecific antigen ( PSA ) relapse incidental prostate cancer ( Gleason score ≤ 3 + 4 PSA &lt; 10ng/mL undergoing active surveillance treatment naive ) . Patients surveillance low risk prostate cancer also eligible please discuss medical monitor . 11 . Mean rest QT interval correct heart rate ( QTc ) &gt; 470ms calculated triplicate electrocardiogram ( ECGs ) . 12 . Evidence significant uncontrolled concomitant disease could affect compliance protocol interpretation result , include significant liver disease ( cirrhosis , uncontrolled major seizure disorder , superior vena cava syndrome ) . 13 . Any unresolved toxicity CTCAE grade &gt; 2 previous anticancer therapy . Patients irreversible toxicity reasonably expect exacerbated IMP may include e.g . hearing loss , peripheral neuropathy etc . 14 . Any prior Grade ≥3 immunerelated adverse event ( irAE ) receive previous immunotherapy agent , unresolved irAE &gt; Grade 1 . 15 . Active prior document autoimmune disease within past 2 year include limited myasthenia gravis , myositis , autoimmune hepatitis , systemic lupus erythematosus , rheumatoid arthritis , inflammatory bowel disease , vascular thrombosis associate antiphospholipid syndrome , Wegener 's granulomatosis , Sjögren 's syndrome , GuillainBarré syndrome , multiple sclerosis , vasculitis , glomerulonephritis . NOTE : Subjects vitiligo , Grave 's disease , psoriasis require systemic treatment ( within past 2 year ) exclude . Patients history autoimmunerelated hypothyroidism stable dose thyroidreplacement hormone may eligible study . 16 . Active prior document inflammatory bowel disease ( e.g. , Crohn 's disease , ulcerative colitis ) history gastrointestinal disorder ( medical disorder extensive surgery ) may interfere absorption study drug 17 . History primary immunodeficiency 18 . History allogeneic prior allogeneic stem cell solid organ transplant 19 . History hypersensitivity MEDI4736 , tremelimumab , excipient history severe allergic , anaphylactic , hypersensitivity reaction chimeric humanize antibody fusion proteins 20 . History hypersensitivity savolitinib excipients . 21 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , uncontrolled hypertension ( SBP &gt; 160mmHg Diastolic blood pressure &gt; 100mmHg , patient value level must blood pressure control medication prior start treatment ) , unstable angina pectoris , cardiac arrhythmia , factor increase risk QTc prolongation , clinically important abnormality rhythm , conduction morphology rest ECGs , active peptic ulcer disease gastritis , Type I diabetes mellitus , active bleeding diatheses include subject know evidence acute chronic hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) , psychiatric illness/social situation would limit compliance study requirement compromise ability subject give write informed consent 22 . Significant cardiovascular disease , New York Heart Association cardiac disease ( Class II great ) , myocardial infarction within 3 month prior enrolment , Patients know leave ventricular ejection fraction ( LVEF ) &lt; 40 % exclude . 23 . Major surgical procedure within 4 week prior enrolment , minor surgical procedure within 7 day enrolment anticipation need major surgical procedure course study diagnosis 24 . History idiopathic pulmonary fibrosis ( include pneumonitis ) , druginduced pneumonitis , organize pneumonia ( i.e. , bronchiolitis obliterans , cryptogenic organize pneumonia ) , evidence active pneumonitis screen chest CT scan ( History radiation pneumonitis radiation field ( fibrosis ) permit ) . 25 . Active tuberculosis know history previous clinical diagnosis tuberculosis . 26 . History leptomeningeal carcinomatosis 27 . Female subject pregnant breastfeed 28 . Any condition , opinion investigator , would interfere evaluation study treatment interpretation patient safety study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>